Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison

被引:8
|
作者
Ward, Zoe [1 ]
Mafirakureva, Nyashadzaishe [1 ]
Stone, Jack [1 ]
Keevans, Mary [2 ]
Betts-Symonds, Graham [2 ,3 ]
Crowley, Desmond [4 ]
McHugh, Tina [5 ]
Avramovic, Gordana [6 ]
Lambert, John S. [5 ,6 ]
Vickerman, Peter [1 ]
机构
[1] Univ Bristol, Bristol, Avon, England
[2] Irish Prison Serv, Dublin, Ireland
[3] Irish Red Cross, Dublin, Ireland
[4] Irish Coll Gen Practitioners, Dublin, Ireland
[5] Mater Misericordiae Univ Hosp, Dublin, Ireland
[6] Univ Coll Dublin, Sch Med, Dublin, Ireland
基金
美国国家卫生研究院;
关键词
Ireland; People who inject drugs; Cost-effectiveness; Prison; Hepatitis C virus; Direct acting antivirals; INJECT DRUGS; PUBLIC-HEALTH; INFECTION; PEOPLE; HCV; METAANALYSIS; PREVENTION; SOFOSBUVIR; MORTALITY; IMPACT;
D O I
10.1016/j.drugpo.2021.103394
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: In Irish prisons, there is a high proportion of people who inject drugs (PWID; 26%) and a high prevalence of HCV (16%), making prison a high priority setting for HCV testing and treatment. We evaluate the cost-effectiveness of a mass HCV screening intervention in Mountjoy Prison, Dublin, compared to the standard-of-care of intermittent screening on committal. Methods: Primary cost data was collected from the intervention using an overall provider perspective. Standard-of-care (SOC) costs were estimated through interview. All costs were inflated to 2020 Euros. An HCV transmission and disease progression model among incarcerated and community PWID and ex-injectors was calibrated to the Dublin HCV epidemic, allowing inclusion of population-level health benefits. The model used intervention data, suggesting 419 individuals were screened, 50 HCV infections diagnosed and 32 individuals initiated treatment, to project the resulting costs and health benefits (quality adjusted life years or QALYs) over 50 years with 5% discounting. The incremental cost effectiveness ratio (ICER), cost per QALY gained, was estimated for the screening intervention compared to the standard-of-care. Probabilistic sensitivity analyses (PSA) determined the probability that the intervention was cost-effective compared to a willingness-to-pay threshold of (sic)30,000/QALY as used in Ireland. The ICER for 1- or 3-yearly mass screening in all Dublin prisons was also calculated. Results: The total direct costs of the intervention (not including treatment drug costs) was (sic)82,392, with most costs being due to staff(43%) and overhead or management costs (38%). Despite having little epidemiological impact due to the small numbers treated, over 50 years the incremental cost of the intervention was (sic)36,592 and 3.8 QALYs were gained, giving a mean ICER of (sic)9,552/QALY. The majority (84%) of PSA runs were below the willingness-to-pay threshold. Yearly mass screening had an ICER of (sic)2,729/QALY compared to SOC and gave a higher net monetary benefit ((sic)7,393,382) than screening every 3 years ((sic)6,252,816). Conclusion: Prison mass screening could be a cost-effective initiative for increasing testing and treatment of HCV in Ireland.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands
    Eijsink, Job F. H.
    Al Khayat, Mohamed N. M. T.
    Boersma, Cornelis
    ter Horst, Peter G. J.
    Wilschut, Jan C.
    Postma, Maarten J.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2021, 22 (01): : 75 - 88
  • [22] Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations
    Coward, Stephanie
    Leggett, Laura
    Kaplan, Gilaad G.
    Clement, Fiona
    BMJ OPEN, 2016, 6 (09):
  • [23] Screening blood donors for hepatitis C virus: the challenge to consider cost-effectiveness
    Kiely, Philip
    TRANSFUSION, 2015, 55 (06) : 1143 - 1146
  • [24] Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States
    Tatar, Moosa
    Keeshin, Susana W.
    Mailliard, Mark
    Wilson, Fernando A.
    JAMA NETWORK OPEN, 2020, 3 (09)
  • [25] Cost-effectiveness of chronic hepatitis C screening and treatment
    Lee, Hye Won
    Lee, Hankil
    Kim, Beom Kyung
    Chang, Young
    Jang, Jae Young
    Kim, Do Young
    CLINICAL AND MOLECULAR HEPATOLOGY, 2022, 28 (02) : 164 - 173
  • [26] Cost-effectiveness of targeted screening for hepatitis C in The Netherlands
    Helsper, C. W.
    Borkent-Raven, B. A.
    De Wit, N. J.
    Van Essen, G. A.
    Bonten, M. J. M.
    Hoepelman, A. I. M.
    Janssen, M. P.
    De Wit, G. A.
    EPIDEMIOLOGY AND INFECTION, 2012, 140 (01): : 58 - 69
  • [27] COST-EFFECTIVENESS OF TARGETED SCREENING FOR HEPATITIS C IN THE NETHERLANDS
    Helsper, C. W.
    Borkent-Raven, B. A.
    de Wit, N. J.
    van Essen, G. A.
    Bonten, M.
    Janssen, M. P.
    Hoepelman, I
    De Wit, G. A.
    VALUE IN HEALTH, 2009, 12 (07) : A429 - A429
  • [28] A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies
    Susich, Marguerite
    Hersh, Alyssa R.
    Greiner, Karen
    Chaiken, Sarina R.
    Caughey, Aaron B.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (25): : 7381 - 7388
  • [29] Treatment of hepatitis C in prison: cost-effectiveness demonstrated by mathematical modelling
    Watson, K. J. R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A330 - A330
  • [30] A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers
    Epstein, Rachel L.
    Pramanick, Tannishtha
    Baptiste, Dimitri
    Buzzee, Benjamin
    Reese, Peter P.
    Linas, Benjamin P.
    Sawinski, Deirdre
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (02): : 205 - 219